sLEP-R ELISA is for the quantitative determination of human soluble leptin receptor (sLEP-R), product number R07.
The adipokine leptin realizes signal transduction via four different leptin receptor (LEP-R) isoforms. However, the amount of functionally active LEP-R is influenced by constitutive cleavage of the extracellular domain. The product of the cleavage process, called soluble leptin receptor (sLEP-R), is the major binding protein for leptin in human blood and modulates its bioavailability. Concentrations of sLEP-R are differentially regulated in metabolic disorders, such as type 1 diabetes mellitus or obesity, and may therefore increase or decrease leptin sensitivity. Lipotoxicity and apoptosis increase LEP-R cleavage via ADAM10-dependent mechanisms. In contrast, although increased levels of sLEP-R appear to directly inhibit leptin effects, reduced levels of sLEP-R may reflect decreased membrane expression of LEP-R. These results explain, in part, changes in leptin sensitivity that are related to changes in serum sLEP-R concentrations observed in metabolic disorders.
|sLEP-R ELISA||Soluble Leptin Receptor ELISA|
|regulatory status (EU)||RUO|
|Calibration||Recombinant eukaryotically expressed soluble leptin receptor.|
|Incubation period||5 h|
|Antibody||Specific high-affinity antibodies|
|Standard||8 individual standards, 0-30 ng/mL|
|Sample matrix||Serum / Plasma|
|Intra-/Interassay Variance [%]||< 10%|